Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7225524 | 1.00 | CES2 (0.39) | CES2CES1LMNAALDH1A1KDM4E | |
| SCHEMBL12714331 | 0.83 | CES2 (0.41) | CES2CES1LMNAALDH1A1KDM4E | |
| SCHEMBL11809743 | 0.81 | KDM4E (0.41) | CES2CES1LMNAALDH1A1KDM4E | |
| SCHEMBL1635308 | 0.80 | GABRA1 (0.50) | LMNAALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL29567244 | 0.80 | GABRA1 (0.50) | LMNAALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL13304309 | 0.79 | CYP3A4 (0.38) | CES2CES1LMNAALDH1A1KDM4E | |
| Hydrogen Peroxide SCHEMBL1652481 | 0.78 | GABRA1 (0.48) | LMNAALDH1A1HPGDMAPTKMT2A | |
| SCHEMBL965996 | 0.78 | LMNA (0.48) | CES2CES1LMNAALDH1A1KDM4E | |
| SCHEMBL378837 | 0.78 | LMNA (0.48) | CES2CES1LMNAALDH1A1KDM4E | |
| SCHEMBL31681943 | 0.78 | LMNA (0.48) | CES2CES1LMNAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755983-B1 | SUBSTITUTED CARBONYLOXYMETHYLPHOSPHORAMIDATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-03-15 | — | — | EP | claimed |
| WO-2024145662-A1 | 2-SUBSTITUTED THIAZOLE AND BENZOTHIAZOLE COMPOSITIONS AND METHODS AS DUX4 INHIBITORS | ALTAY THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024112705-A1 | BORONIC ACID AND BORONATE COMPOSITIONS AND METHODS | ELIMA THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20240101562-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME | HOLOSMEDIC (KR) | 2024-03-28 | — | — | US | disclosed |
| US-11866515-B2 | Hemiasterlin derivatives for conjugation and therapy | SUTRO BIOPHARMA, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20230139442-A1 | MODIFIED AMINO ACIDS | SUTRO BIOPHARMA, INC. | 2023-05-04 | — | — | US | disclosed |
| EP-4174068-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME | Holosmedic (KR) | 2023-05-03 | — | — | EP | disclosed |
| US-11548852-B2 | Modified amino acids | SUTRO BIOPHARMA, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| CN-107428801-B | Hemiasterlin derivatives for coupling and therapy | 苏特罗生物制药公司 | 2022-12-20 | — | — | CN | disclosed |
| US-20060122146-A1 | Preparation of 2'-fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives | GILEAD SCIENCES, INC. | 2006-06-08 | — | — | US | disclosed |
| EP-1656093-A2 | NUCLEOSIDES FOR TREATMENT OF INFECTION BY CORONA VIRUSES, TOGA VIRUSES AND PICORNA VIRUSES | Idenix (Cayman) Limited (KY) | 2006-05-17 | — | — | EP | disclosed |
| EP-1576138-A2 | 2-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE MUTATION | Idenix (Cayman) Limited (KY) | 2005-09-21 | — | — | EP | disclosed |
| EP-1525209-A2 | 1'-, 2'- AND 3' -MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS | Idenix (Cayman) Limited (KY) | 2005-04-27 | — | — | EP | disclosed |
| WO-2005020884-A2 | NUCLEOSIDES FOR TREATMENT OF INFECTION BY CORONA VIRUSES, TOGA VIRUSES AND PICORNA VIRUSES | IDENIX (CAYMAN) LIMITED (KY) | 2005-03-10 | — | — | WO | disclosed |
| US-20050031588-A1 | With purine or pyrimidine base; for use in combination with drugs that induce mutation in Flaviviridae at location other than mutation of nucleotide that results in change from serine to a different amino acid in highly conserved consensus sequence XRXSGXXXT of domain B of the RNA polymerase region | IDENIX PHARMACEUTICALS LLC | 2005-02-10 | — | — | US | disclosed |
| WO-2004046331-A2 | 2’-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE MUTATION | IDENIX (CAYMAN) LIMITED (KY) | 2004-06-03 | — | — | WO | disclosed |
| US-20040077587-A1 | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004003000-A2 | 1’-, 2'- AND 3'- MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX (CAYMAN) LIMITED (KY) | 2004-01-08 | — | — | WO | disclosed |
| WO-1999011625-A1 | HUPERZINE A DERIVATIVES | MACRO HI-TECH JV, LTD. (US) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050031588-A1 | With purine or pyrimidine base; for use in combination with drugs that induce mutation in Flaviviridae at location other than mutation of nucleotide that results in change from serine to a different amino acid in highly conserved consensus sequence XRXSGXXXT of domain B of the RNA polymerase region | PNP, NSUN2, RNGTT | CES2 1237/4885CES1 1569/4885LMNA 1261/4885 |
| US-11548852-B2 | Modified amino acids | PTMS, DNPEP, ANPEP | CES2 2466/4885CES1 2975/4885LMNA 2608/4885 |
| US-11866515-B2 | Hemiasterlin derivatives for conjugation and therapy | CYP17A1, HSD17B7, SHBG | CES2 4602/4885CES1 2801/4885LMNA 1536/4885 |
| US-20240101562-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME | SLC11A2, ABCC1, TSG101 | CES2 3970/4885CES1 1602/4885LMNA 2799/4885 |
| US-20040077587-A1 | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | NSUN2, BCDIN3D, METTL16 | CES2 560/4885CES1 672/4885LMNA 3635/4885 |
| US-20230139442-A1 | MODIFIED AMINO ACIDS | PTMS, DNPEP, ANPEP | CES2 2466/4885CES1 2975/4885LMNA 2608/4885 |
| US-20060122146-A1 | Preparation of 2'-fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives | NSUN2, FBL, RNGTT | CES2 1171/4885CES1 1078/4885LMNA 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.